GGrantIndex
Sort

50,496 grants matching lung cancer

Vaccine and Drug Combination Therapy for Human Cancers

$524,358
James Hodge · Division Of Basic Sciences - Nci · ZIA · FY2013 · CA

Vaccine and radiation for the therapy of human cancers

$524,358
James Hodge · Division Of Basic Sciences - Nci · ZIA · FY2013 · CA

PROMISE Trial: Substudy to Assess for Effective Dose of Radiation

$524,281
Andrew Einstein · Columbia University Health Sciences · R01 · FY2015 · HL

Elucidating pro-metastatic collagen modifying activities of lysyl hydroxylase 2

$524,219
Jonathan M Kurie · University Of Tx Md Anderson Can Ctr · R01 · FY2024 · CA

Reducing cardiac toxicity with deep learning and MRI-guided radiation therapy

$524,106
Carri Kaye Glide-Hurst · University Of Wisconsin-Madison · R01 · FY2021 · HL

UCSF Project 1

$524,054
Trever G Bivona · University Of California, San Francisco · U54 · FY2021 · CA

Improving Risk Factors for Diabetes Complications in Primary Care

$524,031
Polly H Noel · University Of Texas Hlth Science Center · R18 · FY2011 · DK

Study the role(s) of p53 in embryonic stem cells

$524,002
Jing Huang · Division Of Basic Sciences - Nci · ZIA · FY2013 · CA

Customized nanofibers with preferential lung-targeting properties for treating metastatic pulmonary tumors

$523,990
Vanessa Bellat · Weill Medical Coll Of Cornell Univ · R37 · FY2025 · CA

PRAGMATIC CLUSTER RANDOMIZED TRIAL OF AN ASTHMA INTERVENTION FOR URBAN TEENS

$523,906
Mei Lu · Henry Ford Health System · R01 · FY2015 · HL

Development of FISH Molecular Diagnostics to support Clinical Trials at NCI

$523,886
Svetlana Pack · Division Of Basic Sciences - Nci · ZID · FY2012 · CA

Role of ACER2 in cancer chemoresistance and metastasis

$523,880
Cungui Mao · State University New York Stony Brook · R01 · FY2022 · CA

Investigating the heterogeneity of glucose transport in lung adenocarcinoma

$523,834
Claudio Scafoglio · University Of California Los Angeles · R01 · FY2020 · CA

Development of a RUVBL1/2 Inhibitor as a Radiosensitizer and Immune Stimulator for NSCLC

$523,830
Ralf Kittler · Ut Southwestern Medical Center · R01 · FY2024 · CA

Project 2: Optimization of HPPH for HNSCC Selectivity

$523,814
Ravindra K Pandey · Roswell Park Cancer Institute Corp · P01 · FY2016 · CA

Early change in plasma tumor DNA as a patient and trial-level diagnostic in advanced lung cancer

$523,812
Cloud Peter Paweletz · Dana-Farber Cancer Inst · R01 · FY2021 · CA

ALPHA 1 AD CARRIERS AND LUNG CANCER RISK

$523,787
Mayo Clinic Coll Of Medicine, Rochester · R01 · FY2002 · CA

Chemoprevention of Lung Cancer with Mitochondria-Targeted Honokiol

$523,684
Ming You · Methodist Hospital Research Institute · R01 · FY2021 · CA

Cell-of-Origin Footprints of Passenger Mutations in Human Lung Cancer

$523,680
Marcin Imielinski · New York University School Of Medicine · R37 · FY2025 · CA

Mechanisms of Dual Inhibition of TGFbeta/PD-L1 in HNSCC

$523,661
Xiao-Jing Wang · University Of California At Davis · R01 · FY2023 · DE

Targeting Lymph Node Dependent Immune Tolerance in Cancer

$523,629
Edgar G. Engleman · Stanford University · R01 · FY2022 · CA

Mutational Signatures of a Combined Environmental Exposure: Arsenic and Ultraviolet Radiation

$523,581
Ke Jian Liu · University Of New Mexico Health Scis Ctr · R01 · FY2020 · ES

Biophysical roles of pre-metastatic niche evolution on transport of circulating tumor cells

$523,568
Xuewu Liu · Methodist Hospital Research Institute · U01 · FY2023 · CA

HIERARCHICAL MODELING OF INTERACTIONS IN GENOME-WIDE AND PATHWAY-BASED STUDIES

$523,553
David V Conti · University Of Southern California · R01 · FY2010 · ES

Outcomes of Triaged Family Care in Advanced Cancer

$523,527
University Of Michigan At Ann Arbor · R01 · FY2005 · CA